Allergan And Medicis/Ipsen Battle Over Marketing Advantage Of REMS

FDA's decision to require a Risk Evaluation and Mitigation Strategy for botulinum toxin products has opened up a marketing battle between Allergan's long-standing Botox and Ipsen/Medicis' the new-to-the-block Dysport